- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
August 24, 2026 | Pharmaceutical Technology The post A Strategic Shift for Gene Therapies: Manufacturing and Market Size Take Centre Stage first appeared on 4DMT.
June 17, 2026 | RBC Capital Markets The post 4DMT Targets Global Retina Market with Long-lasting Genetic Treatment first appeared on 4DMT.
August 11, 2026 | Healio The post 4D-150 Gene Therapy Reduces Treatment Burden in Wet AMD first appeared on 4DMT.
July 23, 2026 | Ophthalmology Times The post 4DMT’s 2-year PRISM Data Show Durable Treatment Burden Reduction with 4D-150 in Wet AMD first appeared on 4DMT.
July 22, 2026 | Modern Retina The post ASRS 2026: 4D-150 Gene Therapy Shows Sustained Treatment-burden Reduction in Wet AMD at 2 years first appeared on 4DMT.
July 20, 2026 | MedPage Today The post Dramatic Results Seen With Gene Therapy for Age-Related Macular Degeneration first appeared on 4DMT.
June 30, 2026 | Ophthalmology Times The post 4DMT Completes Enrollment in 4FRONT-2, Global Phase 3 Trial of 4D-150 in Wet AMD first appeared on 4DMT.
June 29, 2026 | Eyewire News The post 4DMT Completes Enrollment in Second Phase 3 Trial of 4D-150 for Wet AMD first appeared on 4DMT.
February/March Edition | Fortune The post The Onyx Life Sciences Report: Companies we’re watching in 2026 first appeared on 4DMT.
February 6, 2026 | Scrip The post Scrip Asks… What Does 2026 Hold For Biopharma? Part 4: R&D Innovation first appeared on 4DMT.